GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (NAS:CLSD) » Definitions » Cyclically Adjusted FCF per Share

Clearside Biomedical (Clearside Biomedical) Cyclically Adjusted FCF per Share : $-1.23 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Clearside Biomedical Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Clearside Biomedical's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.113. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.23 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-10), Clearside Biomedical's current stock price is $1.22. Clearside Biomedical's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-1.23. Clearside Biomedical's Cyclically Adjusted Price-to-FCF of today is .


Clearside Biomedical Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Clearside Biomedical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Cyclically Adjusted FCF per Share Chart

Clearside Biomedical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Clearside Biomedical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -1.23

Competitive Comparison of Clearside Biomedical's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Clearside Biomedical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Cyclically Adjusted Price-to-FCF falls into.



Clearside Biomedical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Clearside Biomedical's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.113/131.7762*131.7762
=-0.113

Current CPI (Mar. 2024) = 131.7762.

Clearside Biomedical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 98.326 0.000
201409 0.000 100.428 0.000
201412 -0.227 99.070 -0.302
201503 -0.305 99.621 -0.403
201506 -0.259 100.684 -0.339
201509 -0.257 100.392 -0.337
201512 -0.312 99.792 -0.412
201603 -0.271 100.470 -0.355
201606 -0.665 101.688 -0.862
201609 -0.311 101.861 -0.402
201612 -0.263 101.863 -0.340
201703 -0.447 102.862 -0.573
201706 -0.457 103.349 -0.583
201709 -0.531 104.136 -0.672
201712 -0.595 104.011 -0.754
201803 -0.584 105.290 -0.731
201806 -0.612 106.317 -0.759
201809 -0.616 106.507 -0.762
201812 -0.757 105.998 -0.941
201903 -0.371 107.251 -0.456
201906 -0.267 108.070 -0.326
201909 -0.157 108.329 -0.191
201912 0.040 108.420 0.049
202003 -0.064 108.902 -0.077
202006 -0.071 108.767 -0.086
202009 -0.057 109.815 -0.068
202012 -0.090 109.897 -0.108
202103 -0.097 111.754 -0.114
202106 -0.120 114.631 -0.138
202109 -0.055 115.734 -0.063
202112 0.077 117.630 0.086
202203 0.064 121.301 0.070
202206 -0.090 125.017 -0.095
202209 -0.103 125.227 -0.108
202212 -0.093 125.222 -0.098
202303 -0.120 127.348 -0.124
202306 -0.104 128.729 -0.106
202309 -0.105 129.860 -0.107
202312 0.006 129.419 0.006
202403 -0.113 131.776 -0.113

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Clearside Biomedical  (NAS:CLSD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Clearside Biomedical Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearside Biomedical (Clearside Biomedical) Business Description

Industry
Traded in Other Exchanges
Address
900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Executives
Charles A. Deignan officer: Chief Financial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
George M Lasezkay director 1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101
Bradford T Whitmore 10 percent owner 5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Clay Thorp director, 10 percent owner C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Thomas Ciulla officer: Chief Medical Officer C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005
Benjamin R Yerxa director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Daniel H. White director, officer: President and CEO C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Brion S. Raymond officer: Chief Commercial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Christy L Shaffer director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Hatteras Venture Advisors Iv Sbic, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
Hatteras Venture Advisors Iii, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701

Clearside Biomedical (Clearside Biomedical) Headlines

From GuruFocus